Deerfield Management Boosts Its Stake in OvaScience Inc (OVAS)

Deerfield Management, led by James E. Flynn, revealed in a filing with the Securities and Exchange Commission that it has upped its stake in OvaScience Inc (NASDAQ:OVAS) to 1.8 million shares from 605,600 shares held at the end of the fourth quarter of 2013. The current passive stake amasses 7.6% of the company’s common stock.

OvaScience Inc (NASDAQ:OVAS)

OvaScience Inc (NASDAQ:OVAS) is a global life sciences company that discovers, develops and commercializes new fertility treatments.

Recently, OvaScience Inc (NASDAQ:OVAS) conducted a public offering of 5.0 million shares of common stock at a price of $10.00 per share. The company will use the net proceed from the offering to fund OvaPrimeSM preclinical studies and the anticipated 2015 international launch, expand the AUGMENTSM international launch, establish an international subsidiary and for other general corporate purposes.

The underwriters of the public offering were granted a 30-day option to purchase up to an additional 750,000 shares of common stock of the company.

Last month, OvaScience posted its results for the fourth quarter and the fiscal year 2013. The net loss was 11.0 million, versus a net loss of $4.2 million in the fourth quarter of 2012. For the full year, the net loss amounted to $29.0 million, compared to $13.5 million in the previous year. The increase of the loss was due to a one-time charge of $4.7 million for a technology access fee, with respect to the company’s collaboration with Intrexon, and also due to the high personnel costs, which includes stock-based compensation.

In addition, during the last year, OvaScience Inc (NASDAQ:OVAS) issued $2.5 million of common stock to Intrexon under the collaboration agreement and the remainder will be paid in December 2014. There was also a rise in the research and development expense to $15.8 million in 2013, from $6.3 million in 2012.

Hal Mintz’s Sabby Capital is another hedge fund that is bullish on OvaScience Inc, which holds 152,336 shares, worth $1.4 million.

Last week, Christoph Westphal and Richard Aldrich, director at OvaScience Inc, purchased 100,000 shares. Michelle Dipp, President & CEO and Longwood Fund, L.p., a large shareholder of the company also purchased 100,000 shares each of OvaScience. All three insiders purchased the securities at the public offering price of $10.00 per share.

Deerfield Management focuses on healthcare companies and specializes in funding R&D, corporate transitions, managing hostile takeovers and financial advisory services.

Last month, Deerfield Management boosted its position in Auspex Pharmaceuticals Inc (NASDAQ:ASPX), by buying 700,000 shares and revealed owning 1.9 million shares of the company. The fund also added 350,000 shares of Cara Therapeutics Inc. (NASDAQ:CARA). The fund also added KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) to its equity portfolio, the previous month, and revealed holding 3.18 million shares of the company.

Disclosure: none

Recommended Readings:

Deerfield Management Further Raises Its Position in Auspex Pharmaceuticals Inc (ASPX)

Deerfield Management Adds Cara Therapeutics Inc. (CARA) To Its Equity Portfolio

Deerfield Management Reports New Stake in KaloBios Pharmaceuticals Inc (KBIO)

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

The 10 Most Peaceful Countries in the World

5 Big Reasons Communism Failed

The 15 Most Famous Carl Icahn Quotes

10 Scary Animals that are Actually Harmless

The 8 Most Famous Singer-Actors in Entertainment

The 10 Longest Wars of All Time

The 13 Worst Looking Foods that Taste Great

The 6 Most Gruesome Injuries Suffered During a Sports Match

The 20 Biggest Contracts in MLB History

The 7 Worst Blown Calls in Sports History

7 Free Ways to Advertise Your Business Online

The 18 Best R&B Songs of the 90’s

The 10 Most Dangerous States to be a Cop

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!